Beacon Intelligence to accelerate growth in life sciences R&D intelligence with new investment from Corten Capital

London, 21 May 2026 – Beacon Intelligence (“Beacon”), the leading global data and intelligence platform for life sciences R&D, today announces a majority investment from Corten Capital (“Corten”) to support the next phase of its growth. Corten is a specialist private equity investor in business software, services, and data. Beacon was incubated within the Hanson Wade Group and, with the support of Graphite Capital, scaled into a platform relied upon by the world’s leading pharmaceutical and biotechnology companies. Beacon will operate as a standalone company under Corten’s ownership, following the completion of the transaction which is expected to occur by the end of June 2026.

Beacon was founded in 2015 within the Hanson Wade Group to address a critical gap in structured, granular data on early-stage drug development. The platform is now used daily by over 300 customer organisations globally, including 24 of the world’s 30 largest pharmaceutical companies, to track competitive pipelines, identify licensing and acquisition opportunities, and inform R&D investment decisions. The company has built a unique dataset within 16 distinct modules covering complex modalities in drug development, including ADCs, Bispecifics, and RNA, alongside a growing suite of disease-based modules including Oncology and Neuroscience, with further coverage extensions planned.

With Corten’s support, Beacon will continue to invest in its platform and expand its presence across the life sciences industry.

Rob Poolman, CEO, Beacon Intelligence, commented: “Beacon has been built by an exceptional team of scientists, engineers and commercial colleagues, united by a belief that better data improves drug development decisions and delivers better outcomes for patients. I would like to thank the entire team at Graphite Capital and the wider Hanson Wade team for their support in helping us reach this stage. With Corten’s partnership, we see a significant opportunity to deepen our platform, expand our data coverage, and strengthen our position as the intelligence partner of choice for the world’s leading pharmaceutical and biotech companies.”

Sati S. Sian, Chair, Beacon Intelligence, commented: “Beacon has established itself as a trusted intelligence platform for the life sciences industry, distinguished by the quality of its data and the strength of its scientific expertise. Over the past several years, the business has evolved significantly in both scale and strategic importance, becoming a platform that the world’s leading drug developers rely on every day. I am delighted to continue as Chair and look forward to working with Corten and the management team as Beacon enters this next chapter.”

With this new chapter, Beacon reaffirms its commitment to scientific excellence and to providing the life sciences industry with the trusted, decision-grade intelligence it needs to bring better therapies to patients faster.

 

For further information, please contact:

Rob Poolman, CEO, Beacon Intelligence, Tel: +44 (0)20 3821 6117, email: info@beaconintel.com

Sati S. Sian, Chair, Beacon Intelligence, Tel: +44 (0)20 3821 6117, email: info@beaconintel.com

 

About Beacon Intelligence

Beacon Intelligence is a deep and comprehensive drug development intelligence platform, offering unique technology and drug datasets for complex therapeutics and disease states. Founded in 2015, the company employs 135 people and leverages proprietary ontologies and expert-curated datasets across modality and therapeutic area modules, delivering data, insights, analytics and workflow solutions to the world’s leading pharmaceutical and biotechnology companies at every stage of the drug development journey.

About Corten Capital

Corten Capital is a uniquely focused private equity firm that partners with talented management teams to build market leading B2B Software, Data & Services businesses across Europe and North America. Corten is backed by an exceptional group of university endowments, charitable foundations and family offices from North America, Europe, and Asia, who share its philosophy of investing for long term value creation through technology-led growth and innovation. Since 2020, Corten has raised €1.2 billion across two funds and is currently investing from Corten Capital II, which was closed in March 2024 with €680 million in capital commitments. Corten Advisors UK LLP is authorised and regulated by the Financial Conduct Authority in the UK.

About Graphite Capital

Graphite is a private equity investor in mid-market companies in the UK. The firm focuses on management buy-outs and also invests in development capital opportunities, backing companies with enterprise values of £30 million to £175 million. Graphite’s most recent fund is Graphite Capital Partners IX, which raised £500 million. The sale of Beacon is the fourth successful exit for Graphite in the last 12 months. The firm sold Independence Products Limited, a manufacturer and distributor of infection prevention products, in January this year. This followed the exits of Empowering Learning Group, a provider of training and staffing services to schools, in July 2025 and of Wonderbly, the world-leading publisher of premium personalised books, a month earlier.